Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxart, Inc.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Takeda Takes Alliance Route For Norovirus Vaccine
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
- Drug Delivery
- Other Names / Subsidiaries
- Aviragen Therapeutics, Inc. (Anaconda Pharma SAS
- Biota Holdings Limited
- Biota Pharmaceuticals, Inc.
- Nabi Biopharmaceuticals)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.